Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg

Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›Strength being verifiedDapagliflozin Propanediol Hydrate›Strength being verified
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Yellow to dark yellow oval film-coated double-layer tablet consisting of immediate-release and extended-release layers
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202300348 · Approved 2023.01.27 · Insurance code 642507720

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this drug is one tablet of 5mg/500mg or 10mg/500mg once daily. Gradually titrate the dose to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to this drug from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used as a combination therapy of dapagliflozin and metformin to assist in controlling blood sugar levels in adult patients with type 2 diabetes, in conjunction with diet and exercise therapy. It can also be used in patients with type 2 diabetes who have insufficient blood sugar control and cardiovascular disease or risk factors. However, caution is necessary regarding the risk of cardiovascular events during the use of this medication, and detailed clinical information should be referenced in professional materials. This medication is used to improve blood sugar control and assist in the management of cardiovascular complication risks.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this drug is one tablet of 5mg/500mg or 10mg/500mg once daily. Gradually titrate the dose to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to this drug from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Precautions

This medication is used for the treatment of diabetes and helps to control blood sugar levels. It should not be used in cases where kidney function is impaired or specific health conditions exist. For example, patients with severe renal impairment, serious infections, dehydration, or heart problems may be at risk if they take this medication. Additionally, caution is needed if used with insulin or other diabetes medications as hypoglycemia (a state of excessively low blood sugar) may occur. Pregnant or breastfeeding women should not take this medication, and the safety for children has not been established. This medication can cause a rare but serious side effect called lactic acidosis in some patients. Symptoms include muscle pain, difficulty breathing, weakness, and abdominal pain. If these symptoms occur, consult a doctor immediately. It is recommended to avoid alcohol consumption during treatment with this medication, and to discontinue use for a period before surgery or tests involving iodinated contrast agents. This medication may increase the risk of infections such as genital infections or urinary tract infections; therefore, prompt treatment is required if signs of infection occur. Elderly patients or those with decreased kidney function should use this medication with particular caution, and regular kidney function tests are important. This medication may lower vitamin B12 levels, so blood tests may be needed to check and supplement if necessary. In case of overdose, appropriate treatment is necessary, and since this medication lowers blood sugar, attention should be paid to symptoms of hypoglycemia. Finally, this medication should be stored out of reach of children and kept in its original container to maintain quality.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • related genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • pruritus of the genitalia
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tenosynovitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the medication can be maintained for a long time.

Appearance and packaging

Appearance

Yellow to dark yellow oval film-coated double-layer tablet consisting of immediate-release and extended-release layers

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.